Menu
14/02/2002
Galen Holdings issue quarterly growth figures
Portadown-based company, Galen Holdings have produced a set of results that further underpins the company's recent growth.
Figures for the quarter ended December 31, 2001, showed an increase in operating profit to £16.5 million on a turnover of £53.7 million.
Sale of pharmaceutical products grew by 35 per cent and now account for over 70 per cent of turnover.
Commenting on the results, Roger Boissonneault, Chief Executive Officer, said: “We are very pleased with these results, which demonstrate strong organic growth in our core pharmaceutical business.
“This was a significant quarter for Galen. Sales continue to grow for our key brands while at the same time we continue to build for future success.”
Galen Holdings is an integrated specialty pharmaceutical company focused principally in the women's healthcare and dermatology therapeutic areas.
The company develops, manufactures, supplies and markets branded prescription pharmaceutical products in the United States, United Kingdom and Ireland.
Galen also provide a wide range of services to the research and development organizations of pharmaceutical and biotechnology industry participants in Europe and the United States. (MB)
Figures for the quarter ended December 31, 2001, showed an increase in operating profit to £16.5 million on a turnover of £53.7 million.
Sale of pharmaceutical products grew by 35 per cent and now account for over 70 per cent of turnover.
Commenting on the results, Roger Boissonneault, Chief Executive Officer, said: “We are very pleased with these results, which demonstrate strong organic growth in our core pharmaceutical business.
“This was a significant quarter for Galen. Sales continue to grow for our key brands while at the same time we continue to build for future success.”
Galen Holdings is an integrated specialty pharmaceutical company focused principally in the women's healthcare and dermatology therapeutic areas.
The company develops, manufactures, supplies and markets branded prescription pharmaceutical products in the United States, United Kingdom and Ireland.
Galen also provide a wide range of services to the research and development organizations of pharmaceutical and biotechnology industry participants in Europe and the United States. (MB)
Related Northern Ireland News Stories
Click here for the latest headlines.
28 March 2023
Centred Soul 1000th Community-Pharmacy Partnership Member
Newry-based Centred Soul has been awarded funding to deliver the 1000th Building the Community-Pharmacy Partnership (BCPP) programme to improve the health and wellbeing of women in the local community. The BCPP programme is led by Community Development and Health Network (CDHN) in Northern Ireland and is funded by the Department of Health.
Centred Soul 1000th Community-Pharmacy Partnership Member
Newry-based Centred Soul has been awarded funding to deliver the 1000th Building the Community-Pharmacy Partnership (BCPP) programme to improve the health and wellbeing of women in the local community. The BCPP programme is led by Community Development and Health Network (CDHN) in Northern Ireland and is funded by the Department of Health.
20 May 2022
New Safe Medication Use Campaign Launches
A new campaign to highlight the importance of using medicine safely has been launched by Northern Ireland's Chief Pharmaceutical Officer, Cathy Harrison.
New Safe Medication Use Campaign Launches
A new campaign to highlight the importance of using medicine safely has been launched by Northern Ireland's Chief Pharmaceutical Officer, Cathy Harrison.
30 August 2011
Corporation Tax Defeats Derry Jobs' Bid
An SDLP MLA from Derry has said he has reservations about whether or not a pharmaceutical company ever had any true intention of investing in Londonderry - even though the company boss has said it was purely a financial decision to take the jobs south of the border.
Corporation Tax Defeats Derry Jobs' Bid
An SDLP MLA from Derry has said he has reservations about whether or not a pharmaceutical company ever had any true intention of investing in Londonderry - even though the company boss has said it was purely a financial decision to take the jobs south of the border.
11 April 2008
Waste Plant Threat To Jobs
A leading hi-tech pharmaceutical business - one of Northern Ireland's 'blue chip' companies - isn't wasting time in its attempt to derail a planned waste recycling plant on its doorstep.
Waste Plant Threat To Jobs
A leading hi-tech pharmaceutical business - one of Northern Ireland's 'blue chip' companies - isn't wasting time in its attempt to derail a planned waste recycling plant on its doorstep.
04 July 2001
HOLDINGS WINDFALL FOR GALEN DIRECTORS
THREE Ulster businessmen are to benefit from a share holdings windfall of around £100 million. Galen pharmaceutical group directors, Dr Allen McClay and John King will pick up £40 million each, while finance director Geoffrey Elliott, as well as charitable trust set up by Dr McClay, will receive £10 million each.
HOLDINGS WINDFALL FOR GALEN DIRECTORS
THREE Ulster businessmen are to benefit from a share holdings windfall of around £100 million. Galen pharmaceutical group directors, Dr Allen McClay and John King will pick up £40 million each, while finance director Geoffrey Elliott, as well as charitable trust set up by Dr McClay, will receive £10 million each.
-
Northern Ireland WeatherThis Evening and Tonight:Apart from a little patchy drizzle it will be a dry evening and night with variable amounts of cloud. A few mist and fog patches forming. Minimum temperature 7 °C.
